Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated indications/usage claim that SURVANTA is indicated for prevention and rescue (treatment) of RDS in premature infants is directly supported by the FDA label (Section 1).
Category Scores
Accurate Statements
Survanta is used to help premature babies breathe.
Supported insofar as the label indicates SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) in premature infants (Section 1 — INDICATIONS AND USAGE).
Survanta is indicated for prevention and rescue (treatment) of Respiratory Distress Syndrome (RDS) in premature infants.
Directly supported by Section 1 — INDICATIONS AND USAGE.
Unsupported Statements
Lung surfactant is a substance that coats the air sacs in the lungs.
Not stated in the provided FDA label excerpts for this evaluation (no label text provided that supports this specific mechanism description phrasing).
Lung surfactant helps keep the air sacs open.
Not stated in the provided FDA label excerpts for this evaluation (the label discusses stabilization against alveolar collapse but the exact statement is not explicitly supported by the provided text).
Survanta is an artificial lung surfactant drug.
The label states SURVANTA replenishes surfactant and restores surface activity, but the exact phrasing that it is an 'artificial' surfactant drug is not explicitly supported by the provided label excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only directly label-evaluated claim (indications/usage) is supported; the additional mechanistic/characterization statements are not necessary for safe use assessment and are not contradicted by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some mechanistic/characterization statements (e.g., 'artificial', 'coats air sacs', 'keeps air sacs open') are not explicitly supported by the provided label excerpts, though they are not contradicted.
Suggested Improvement
Limit claims to the label-supported indication language (prevention and treatment/rescue of RDS in premature infants) or use label-excerpt wording from Clinical Pharmacology to describe surfactant function.